Skip to main content
Inventage Lab Inc. logo

Inventage Lab Inc. — Investor Relations & Filings

Ticker · 389470 ISIN · KR7389470006 KO Professional, scientific and technical activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2024-03-21 Legal Proceedings Report
Country KR South Korea
Listing KO 389470

About Inventage Lab Inc.

https://www.inventagelab.com/m/en/

Inventage Lab Inc. is a biopharmaceutical company specializing in the development of advanced Drug Delivery Systems (DDS). The company's foundation is its proprietary microfluidics-based platform technology, Laminar-FluiDigm™, which is applied to pharmaceutical research and manufacturing. Inventage Lab operates two primary platforms: IVL-DrugFluidic® for developing and producing microsphere-based long-acting injectables, and IVL-GeneFluidic® for the formulation and manufacturing of Lipid Nanoparticles (LNPs) for nucleic acid and gene therapies. The company's pipeline is focused on treating chronic and refractory diseases, with key programs targeting androgenic alopecia (male pattern baldness) and Alzheimer's disease. Other development areas include drug re-discovery for conditions like rheumatic arthritis and multiple sclerosis, and collaborative projects for HIV treatments and mRNA-based therapies.

Recent filings

Filing Released Lang Actions
[기재정정]파생상품거래손실발생
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a previously disclosed 'Derivative Trading Loss'. It details financial adjustments related to derivative valuation losses and provides updated figures for equity and loss balances. Since this is a specific regulatory disclosure regarding financial events and corrections, and does not fit into the other specialized categories like M&A or Dividends, it is classified as a Regulatory Filing (RNS).
2024-03-21 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Inventage Lab. It provides the audit opinion (unqualified/proper), key financial data, and details regarding capital impairment and operating losses. While it contains audit-related information, it is a standard regulatory disclosure filing in Korea (DART system) announcing the receipt and submission of the audit report, rather than the full audit report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2023
2024-03-20 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Inventage Lab' (주식회사 인벤티지랩) for the fiscal year ending December 31, 2023. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes. While it contains financial data, it is a formal audit report rather than a full 10-K annual report or a simple earnings release. Based on the provided definitions, 'AR' (Audit Report / Information) is the most accurate classification. FY 2023
2024-03-20 Korean
투자판단관련주요경영사항(임상시험계획변경승인) (알코올 의존성 및 opioid 의존성 치료제(IVL3004) 및 다발성 경화증 치료제(IVL4002) 제1상 임상시험 계획 변경승인)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from a Korean company (Inventage Lab) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the approval of a clinical trial plan amendment. This type of filing is a standard regulatory announcement in the Korean stock market (KRX) for material corporate events. Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a direct regulatory disclosure of a material event, it falls under the 'Regulatory Filings' category.
2024-03-18 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Inventage Lab. It includes the meeting agenda, details on voting, and management information (such as director activities and business outlook). This type of document is a standard proxy statement/information circular provided to shareholders to inform them of upcoming votes and company governance matters, which falls under the 'Proxy Solicitation & Information Statement' category.
2024-03-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Inventage Lab) announcing a significant change (over 30%) in revenue or profit structure. This is a standard mandatory disclosure filing required by the Korea Exchange (KRX) when financial results deviate significantly from previous periods. Since it is a specific regulatory disclosure of financial performance metrics rather than a full annual report or a simple announcement of a report's availability, it falls under the 'Regulatory Filings' category. FY 2023
2024-03-12 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.